Jun 2022
Host: Prof. Charlotte Hauser
Abstract:
Synthetic
biology is now an established interdisciplinary research field which
aims to engineer and re-engineer biological systems for both useful
applications and further our understanding of the rules of life. The
field has grown rapidly over the last 20 years with major public and
private investment. However, despite the enormous progress, the full
promise and potential of synthetic biology has not yet been achieved. In
this talk I will describe some of the advances the field has made over
the last 15 years and discuss the opportunities for transitioning to a
bioeconomy through biomanufacturing. I will introduce the importance of
public-funded biofoundries in nucleating and developing the new
synthetic biology industry as well as advancing the research field and
providing public infrastructure for a pandemic response. Finally, I will
use examples from my own research to highlight some of the
opportunities and technical challenges.
Biography
Professor
Paul Freemont is the co-founder of the Imperial College Centre for
Synthetic Biology and Innovation and co-founder and co-director of the
National UK Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; since 2013) and Director of the London BioFoundry
(since 2016) at Imperial College London. He is also currently the Head
of the Section of Structural and Synthetic Biology in the new Department
of Infectious Diseases at Imperial. He was previously the Head of the
Division of Molecular Biosciences and Centre for Structural Biology
having joined Imperial from Cancer Research UK London Research Institute
(now known as the Crick Research Institute) where he was a Principle
Investigator and Head of Group. In 2019, he led the establishment of the
Global Biofoundry Alliance (GBA)
comprising 23 institutions on four continents aimed at building and
sharing open technology platforms for synthetic biology and currently
the chair of the GBA. His recent research interests are focused on
developing synthetic biology foundational tools and cell-free systems
for specific applications including biosensing and metabolic
engineering. He is author of over 250 scientific publications (H-index
76) and is an elected member of European Molecular Biology Organisation
and Fellow of the Royal Society of Biology, Royal Society of Chemistry
and Royal Society of Medicine and is an Honorary Fellow of the Royal
College of Art. He was a co-author of the British Government's UK
Synthetic Biology Roadmap and was a recent member of the Ad Hoc
Technical Expert Group (AHTEG) on synthetic biology for the United
Nations Convention for Biological Diversity (UN-CBD). He has also
appeared regularly on radio and television broadcasts on the subject of
synthetic biology and has successfully co-supervised Imperial iGEM teams
since 2006.